Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326312 · ClinicalTrials.gov registry record · Phase 2
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
A Phase 2 study, sponsored by GTx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01326312 is a Phase 2 study that was terminated before completion, run by GTx. The registered enrollment target is 159 participants.
The verdict
NCT01326312, a Phase 2 study, was terminated before completion, sponsored by GTx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
Interventions
- DRUG Lupron Depot
- DRUG GTx-758 1000mg
- DRUG GTx-758 2000mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326312
The ClinicalTrials.gov registry entry for NCT01326312 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lupron Depot is the first listed.
NCT01326312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326312 about?
NCT01326312 is a clinical study titled "Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer". The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
What is the current status of trial NCT01326312?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2011-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01326312?
The interventions under investigation include: Lupron Depot (DRUG), GTx-758 1000mg (DRUG), GTx-758 2000mg (DRUG).
Who is sponsoring clinical trial NCT01326312?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.